|
|
|
|
|
非在研适应症- |
最高研发阶段批准上市 |
|
首次获批日期2009-10-16 |
An Open label, randomized, balanced, two treatment, two sequence, two period, crossover, oral dose comparative pharmacokinetic study of TurmXtra 60N Capsule 250 mg (containing 150 mg of curcuminoids from Water Dispersible Turmeric Extract , 1 x 250 mg) (T) manufactured by Nutriventia Limited. with that of Turmeric extract Capsules (containing 500 mg of C3 Complex curcuminoids and 5 mg bioperine,3 x 500 mg, one capsule 6 hourly) (R) manufactured by Sami-Sabinsa Group Limited, India in normal, healthy, adult, human subjects under fasting conditions.
An open label, Balanced, Randomized, Active control clinical trial to compare Safety and Efficacy of Risorine Capsule in adult patients with RNTCP Category I Pulmonary Tuberculosis
Efficacy and Safety Study of Risorine (FDC of Rifampicin 200mg + Isoniazid 300mg + Piperine 10mg) in Patients with Newly Diagnosed Sputum Smear Positive Pulmonary Tuberculosis: a Randomized, Single-blind, Comparative Clinical Trial
100 项与 CYP3A x RNAP x P-gp 相关的临床结果
100 项与 CYP3A x RNAP x P-gp 相关的转化医学
0 项与 CYP3A x RNAP x P-gp 相关的专利(医药)